Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Efficort

Cream & Lipocream

 

COMPOSITION

Efficort Cream contains hydrocortisone aceponate 0.127% w/w as the active ingredeint in an oil-in-water cream base containing self-emulsifying wax, white petrolatum, stearyl alcohol, benzyl alcohol and purified water.

 

Efficort Lipocream contains hydrocortisone aceponate 0.127% w/w as the active ingredient in a water-in-oil cream base containing white petrolatum, aluminium di/tristearate, liquid paraffin, Protegin WX, DUB BW, magnesium sulphate heptahydrate and purified water.

 

PHARMACEUTICAL FORM

Efficort Cream and Lipocream are for cutaneous use only.

 

PHARMACOLOGICAL PROPERTIES

 

Pharmacodynamic properties

Efficort is a potent corticosteroid (class II) qaccording to the European classification.

 

It acts on certain inflammatory and allergic processes occurring in the course f atopic and/or contact dermatitis and on pruriginous effects linked to these processes. It has a vasoconstrictor (anti-exudative) activity adn ti inhibits cellular replication and the synthesis processes in the dermis and epidermis.

 

Pharmacokinetic properties

Systemic absorption measured in terms f the effect on blood cortisol levels occurs after cutaneous application of Efficort

 

The extent of absorption and of systemic effects depends on the area treated and the condition of the epidermis, the duration of the treatment: the more the treatment is prolonged, the greater the likelihood of these effects is, the site of application, the use of occlusive dressings.

 

Preclinical safety data

In animal studies, hydrocortisone aceponate was well tolerated on cutaneous application for periods of up to six months in rats and rabbits. The major symptoms of toxicity found in all animal species by systemic routes of administration were related to adrenocorticosteroid effects, and included alterations of the pituitary-adrenal axis, and a slight anemia. Principal organs of toxicity were the stomach, liver, adrenal, pituitary, lungs and spleen. In the cutaneous route studies hydrocortisone aceponate the majority of these findings were either absent or considerably reduced in magnitude.

 

INDICATIONS AND USAGE

Efficort is recommended for steroid-responsive dermatoses (eczema, atopic dermatitis, psoriasis, lichenification)

 

Efficort Cream is recommended for the treatment of acute exudative lesions.

 

Efficort Lipocream is recommended for the treatment of dry squamous inflammatory lesions.

 

CONTRAINDICATIONS

Hypersensitivity to any ingredient of the preparation, ulcerated lesions, acne and rosacea and conditions for which cutaneous corticosteroid therapy is contra-indicated, notably skin infections of bacterial, viral, fungal and parasitic origin, even when these include an inflammatory response.

 

UNDESIRABLE EFFECTS

Cutaneous application of potent corticosteroids to large areas (30% of the body surface area or more) and/or over long periods (more than 2 weeks) may lead to onset of the following undesirable effects:

Hair follicle inflammation (folliculitis), increased and intensified hair growth (hypertrichosis), skin bleaching (hypopigmentation), so-called steroid-acne and telangiectasia linear skin lesions ( striae cutis distensae, striae atrophicae) affecting notably the limbs (occurring more usually in adolescents), cutaneous atrophy, post-atrophy ecchymoses and fragile skin.

 

Disruption of the pituitary-adrenal axis on systemic uptake of the drug through the skin may also occur, particularly upon occlusive treatment of large areas.

 

Corticosteroids may give rise to perioral dermatitis or create or aggravate rosacea of the face, wound healing may be impaired in the case of atonic wounds, sores, leg ulcers (see Contraindications).

 

Potential systemic effects: see Special Warnings and precautions for use.

 

SPECIAL WARNINGS AND PRECAUTIONS FOR USE

General

The prolonged use on the face of high-potency corticosteroids can give rise to a corticosteroid-induced dermatitis which is paradoxically corticosteroid-responsive. A rebound effect is observed at each interruption of treatment. Progressive and particularly difficult withdrawal is then require.

 

Due to the possibility of absorption of corticosteroids into the general circulation, treatment of large areas or under occlusion may give rise to the effects of systemic corticosteroid therapy, particularly in the infant and small child. These effects consist of Cushing syndrome and growth inhibition: these untoward effects disappear upon interruption of treatment but abrupt withdrawal can result in acute adrenal insufficiency. it is preferable to avoid use of corticosteroids in the infant and particular attention must be given to the likelihood of spontaneous occlusion. In the case of a bacterial or fungal infection of a corticosteroid-responsive dermatosis, either a specific antimicrobial treatment must precede the use of the corticosteroid or possibly, and in only certain cases, a combination of cortico-steroid plus specific treatment may be used.

 

If local intolerance occurs, treatment must be interrupted and the cause investigated.

 

In the event of application to the eyelid, the duration of treatment must be limited. Prolonged application exposes the patient to the risk of ptosis or glaucoma and a rebound effect can be observed.

 

Pregnancy and lactation

The use of Efficort during the first 3 months of pregnancy should be avoided unless the benefit outweighs any potential risks to the fetus.

 

It is not known whether this drug is excreted in animal or human milk. Because many drugs are excreted in human milk, caution should be exercised when Efficort is administered to nursing mothers. In this event, the product should not be used on the chest.

 

Overdose

Efficort is for cutaneous use only. If the medication is applied excessively, no more rapid or better results will be obtained and the undesirable effects described above may be increased and intensified.

 

INTERACTION WITH OTHER MEDICATIONS AND OTHER FORMS OF INTERACTION

Hydrolysis by alkaline agents: do not use alkaline antiseptics prior to applying Efficort.

Incompatibility with oxidative agents.

The concomitant use of other adrenocorticosteroids in the form of tablets, drops or injections may intensify the side effects.

 

DOSAGE AND METHOD OF ADMINISTRATION

Adults

Unless otherwise prescribed, Efficort should be applied once to twice daily in a thin layer over the affected skin areas. For the application to be reasonable it is advisable to dab a small amount of product on to several sites at the affected areas and to gently massage in until it has been completely absorbed.

 

Application should be limited to twice a day. An increase in the number of daily applications would be likely to aggravate the side effects without improving the therapeutic efficacy of the preparation.

 

Treatment of large areas or long term therapy (3 weeks or more) require clinical monitoring. In any case the duration of treatment prescribed by the physician must be strictly observed. If required, an occlusive dressing could be prescribed by the physician.

 

In case of certain dermatological conditions ( psoriasis, dermatitis, ...) a gradual withdrawal might be desirable. this may be achieved by reducing the frequency of application and/ or the use of a more dilute or less potent corticosteroid.

 

Infants and young children

Unless otherwise prescribed, one daily application is generally adequate.

 

Continuous daily treatment should be limited to a short period (about 1 week). If used for a longer duration, periodical steroid-free breaks should be interposed.

 

Occlusive dressings should be avoided in infants and young children.

 

Instructions for use / Handling

Squeeze the tube gently at its base to place a quantity of cream on the fingertips sufficient to cover the area to be treated. Wash hands thoroughly and replace cap tightly after use.

 

EFFECTS ON THE ABILITY TO DRIVE AND USE MACHINES

Based on the pharmacodynamic profile and extensive clinical experience, performance related to driving and using machines should not be affected.

 

SHELF LIFE

This medicine should not be sued after the expiry date (Exp. Date) shown on the pack.

 

STORAGE

Store at room temperature (not exceeding 25C). Keep out of reach of children.

 

CONTAINER

Efficort Cream is packed in 15g and 30g white polypropylene tubes fitted with white polypropylene screw caps.

Efficort Lipocream is packaged in 15g and 30g collapsible aluminium tubes coated internally with an epoxy-phenolic type resin and fitted with white poly propylene screw caps.

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer